Picton Mahoney Asset Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Picton Mahoney Asset Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-274,995	Closed	-$2.78M	–	710
2022 Q4	$2.78M	Hold	274,995	–	–	0.13%	219
2022 Q3	$2.73M	Hold	274,995	–	–	0.1%	233
2022 Q2	$2.69M	Hold	274,995	–	–	0.1%	302
2022 Q1	$2.69M	Buy	274,995 +149,997	+120%	+$1.46M	0.1%	303
2021 Q4	$1.21M	Hold	124,998	–	–	0.03%	540
2021 Q3	$1.22M	Hold	124,998	–	–	0.05%	482
2021 Q2	$1.21M	Buy	+124,998	New	+$1.23M	0.04%	490

Picton Mahoney Asset Management's EBAC Position: Q1 2023 in Review

Picton Mahoney Asset Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 274,995 shares — an estimated $2.78M sold.

Picton Mahoney Asset Management first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $2.78M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Picton Mahoney Asset Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Picton Mahoney Asset Management sold 274,995 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $2.78M.
Picton Mahoney Asset Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Picton Mahoney Asset Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $2.78M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2023, filed 8 May 2023.